Benign giant-cell tumor of the common bile duct: a case report

World J Gastroenterol. 2014 Nov 7;20(41):15448-53. doi: 10.3748/wjg.v20.i41.15448.

Abstract

Primary giant-cell tumors rarely arise in the common bile duct. We herein report a case of primary giant-cell tumor of the common bile duct. The patient was an 81-year-old male who was diagnosed with a well-defined 1.2-cm mass projecting into the lumen of the middle common bile duct. Excision of the gallbladder and extrahepatic bile duct and a Roux-en-Y cholangiojejunostomy were performed. Histologically, the tumor had no association with carcinomas of epithelial origin and was similar to giant-cell tumors of the bone. The tumor consisted of a mixture of mononuclear and multinucleated osteoclast-like giant cells. The mononuclear cells showed no atypical features, and their nuclei were similar to those of the multinucleated giant cells. CD68 was expressed on the mononuclear and multinucleated osteoclast-like giant cells, whereas CD163 immunoreactivity was restricted to the mononuclear cells. Six months after the operation, the patient was still alive and had no recurrence. The interest of this case lies in the rarity of this entity, the difficulty of preoperative diagnosis, and this tumor's possible confusion with other malignant tumors.

Keywords: CD163; Common bile duct; Giant-cell tumor; Surgical resection.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged, 80 and over
  • Anastomosis, Roux-en-Y
  • Antigens, CD / analysis
  • Antigens, Differentiation, Myelomonocytic / analysis
  • Biomarkers, Tumor / analysis
  • Biopsy
  • Cholangiopancreatography, Magnetic Resonance
  • Cholecystectomy
  • Common Bile Duct Neoplasms / immunology
  • Common Bile Duct Neoplasms / pathology*
  • Common Bile Duct Neoplasms / surgery
  • Giant Cell Tumors / immunology
  • Giant Cell Tumors / pathology*
  • Giant Cell Tumors / surgery
  • Humans
  • Immunohistochemistry
  • Jejunostomy
  • Male
  • Receptors, Cell Surface / analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Tumor Burden

Substances

  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Biomarkers, Tumor
  • CD163 antigen
  • CD68 antigen, human
  • Receptors, Cell Surface